Deltanoid Pharmaceuticals Appoints Douglas Jermasek as Chief Executive Officer

Deltanoid Pharmaceuticals, Inc. appointed former Genzyme/Sanofi renal head, Douglas Jermasek as its new Chief Executive Officer. Co-founder Hector F DeLuca, PhD, MD, DSC will continue as Chairman of the Board of Directors and assume the responsibilities of President and Chief Operating Officer. Co-founder Margaret Clagett-Dame, PhD will continue in her role as Executive Vice President.
Co-founder Hector F DeLuca, PhD, MD, DSC commented:

I am proud of the accomplishments of Deltanoid in developing our lead compound through phase 2 and in positioning two other compounds for phase 2 clinical trials. As we now advance our lead program, DP001 for the treatment of secondary hyperparathyroidism (SHPT) to phase 3 clinical development and ultimately commercialization, I am pleased to be turning over the reins to Doug, who brings a 20 year track record of biopharmaceutical industry success and proven leadership in the renal space.

Click here to view the full press release.